At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MRNA Moderna, Inc.
Trading 05-01 12:59:13 EDT
44.90
-1.04
-2.26%
High48.40Low44.05Vol5.49M
Open46.25D1 Closing45.94Amplitude9.47%
Mkt Cap17.73BTradable Cap16.31BTotal Shares394.94M
T/O248.41MT/O Rate1.51%Tradable Shares363.29M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Moderna Tops Revenue Estimates on Stronger International COVID Vaccine Sales
Reuters  ·  05-01 18:51
Moderna Tops Revenue Estimates on Stronger International COVID Vaccine Sales
BUZZ-U.S. STOCKS ON THE MOVE-Paramount Skydance, Newell Brands, Rhythm,
Reuters  ·  05-01 23:58
BUZZ-U.S. STOCKS ON THE MOVE-Paramount Skydance, Newell Brands, Rhythm,
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Illumina (ILMN), Moderna (MRNA) and Dexcom (DXCM)
TIPRANKS  ·  05-01 23:50
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Illumina (ILMN), Moderna (MRNA) and Dexcom (DXCM)
Moderna price target raised to $32 from $31 at BofA
TIPRANKS  ·  05-01 23:21
Moderna price target raised to $32 from $31 at BofA
Moderna Beats Estimates on International Covid Shot Sales -- WSJ
Dow Jones  ·  05-01 22:24
Moderna Beats Estimates on International Covid Shot Sales -- WSJ
Moderna Shares Dip 3.1% After Q1 Results
THOMSON REUTERS  ·  05-01 21:34
Moderna Shares Dip 3.1% After Q1 Results
Moderna Inc reports results for the quarter ended March 31 - Earnings Summary
Reuters  ·  05-01 21:32
Moderna Inc reports results for the quarter ended March 31 - Earnings Summary
Moderna Exec Says Expects Mnexspike and Mcombriax to Contribute to Revenue Growth Starting in 2027
THOMSON REUTERS  ·  05-01 20:13
Moderna Exec Says Expects Mnexspike and Mcombriax to Contribute to Revenue Growth Starting in 2027
Moderna Exec Says Co Does Not Expect Material Impacts From the Ongoing Conflict in the Middle East to 2026 Outlook - Conf Call
THOMSON REUTERS  ·  05-01 20:13
Moderna Exec Says Co Does Not Expect Material Impacts From the Ongoing Conflict in the Middle East to 2026 Outlook - Conf Call
Moderna Exec Says Co Is Awaiting Guidance From FDA on the Next Steps to Resume US Filing for Flu-Covid Combination Vaccine
THOMSON REUTERS  ·  05-01 20:13
Moderna Exec Says Co Is Awaiting Guidance From FDA on the Next Steps to Resume US Filing for Flu-Covid Combination Vaccine
Moderna Exec Says Co Will Continue to Monitor Geopolitical Developments
THOMSON REUTERS  ·  05-01 20:13
Moderna Exec Says Co Will Continue to Monitor Geopolitical Developments
Top Premarket Gainers
MT Newswires Live  ·  05-01 19:51
Top Premarket Gainers
BUZZ-U.S. STOCKS ON THE MOVE-Reddit, Apple, Twilio
Reuters  ·  05-01 19:38
BUZZ-U.S. STOCKS ON THE MOVE-Reddit, Apple, Twilio
Moderna reports Q1 EPS ($3.40), consensus ($3.88)
TIPRANKS  ·  05-01 19:38
Moderna reports Q1 EPS ($3.40), consensus ($3.88)
Moderna Reports Q1 EPS Of $ -3.40
Reuters  ·  05-01 18:53
Moderna Reports Q1 EPS Of $ -3.40
Moderna Shares Extend Gains, Last up 10.8% Premarket
THOMSON REUTERS  ·  05-01 18:46
Moderna Shares Extend Gains, Last up 10.8% Premarket
Earnings Flash (MRNA) Moderna Posts Q1 Loss $3.40 a Share, vs. FactSet Est of $4.45 Loss
MT Newswires Live  ·  05-01 18:41
Earnings Flash (MRNA) Moderna Posts Q1 Loss $3.40 a Share, vs. FactSet Est of $4.45 Loss
Stock Track | Moderna Soars 5.35% in Pre-Market After Q1 Revenue and EPS Beat Estimates on Strong International Vaccine Sales
Stock Track  ·  05-01 18:39
Stock Track | Moderna Soars 5.35% in Pre-Market After Q1 Revenue and EPS Beat Estimates on Strong International Vaccine Sales
BUZZ-Moderna rises after first-quarter revenue beats estimates
Reuters  ·  05-01 18:34
BUZZ-Moderna rises after first-quarter revenue beats estimates
Moderna Q1 EPS $(1.18) Beats $(3.81) Estimate, Sales $389.000M Beat $227.969M Estimate. Adj. EPS excludes Litigation settlement-related expenses of $(2.22).
Benzinga  ·  05-01 18:33
Moderna Q1 EPS $(1.18) Beats $(3.81) Estimate, Sales $389.000M Beat $227.969M Estimate. Adj. EPS excludes Litigation settlement-related expenses of $(2.22).
No data available

Introduction

Company Name.
Moderna, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Issue price:
--